Modern Healthcare Technology Holdings Full Year 2024 Earnings: HK$0.011 loss per share (vs HK$0.023 loss in FY 2023)

Simply Wall St

July 30, 2024

Modern Healthcare Technology Holdings (HKG:919) Full Year 2024 Results

Key Financial Results

Revenue: HK$457.4m (up 12% from FY 2023).
Net loss: HK$9.57m (loss narrowed by 54% from FY 2023).
HK$0.011 loss per share (improved from HK$0.023 loss in FY 2023).

revenue-and-expenses-breakdown — SEHK:919 Revenue and Expenses Breakdown July 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Beauty and Wellness Services segment contributing a total revenue of HK$419.7m (92% of total revenue). Notably, cost of sales worth HK$308.8m amounted to 68% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Depreciation & Amortisation (D&A) costs, amounting to HK$76.6m (48% of total expenses). Explore how 919's revenue and expenses shape its earnings.

Modern Healthcare Technology Holdings' share price is broadly unchanged from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Modern Healthcare Technology Holdings (at least 1 which makes us a bit uncomfortable), and understanding these should be part of your investment process.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com